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Abstract
Single Nucleotide Polymorphisms (SNPs) in genes involved in the DNA Base Excision Repair (BER) pathway could be
associated with cancer risk in carriers of mutations in the high-penetrance susceptibility genes BRCA1 and BRCA2, given the
relation of synthetic lethality that exists between one of the components of the BER pathway, PARP1 (poly ADP ribose
polymerase), and both BRCA1 and BRCA2. In the present study, we have performed a comprehensive analysis of 18 genes
involved in BER using a tagging SNP approach in a large series of BRCA1 and BRCA2 mutation carriers. 144 SNPs were
analyzed in a two stage study involving 23,463 carriers from the CIMBA consortium (the Consortium of Investigators of
Modifiers of BRCA1 and BRCA2). Eleven SNPs showed evidence of association with breast and/or ovarian cancer at p,0.05 in
the combined analysis. Four of the five genes for which strongest evidence of association was observed were DNA
glycosylases. The strongest evidence was for rs1466785 in the NEIL2 (endonuclease VIII-like 2) gene (HR: 1.09, 95% CI (1.03–
1.16), p = 2.761023) for association with breast cancer risk in BRCA2 mutation carriers, and rs2304277 in the OGG1 (8-
guanine DNA glycosylase) gene, with ovarian cancer risk in BRCA1 mutation carriers (HR: 1.12 95%CI: 1.03–1.21,
p = 4.861023). DNA glycosylases involved in the first steps of the BER pathway may be associated with cancer risk in BRCA1/
2 mutation carriers and should be more comprehensively studied.
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Introduction
Carrying an inherited mutation in the BRCA1 or BRCA2 gene
increases a woman’s lifetime risk of developing breast, ovarian and
other cancers. The estimated cumulative risk of developing breast
cancer by the age of 70 in BRCA1 and BRCA2 mutation carriers
varies between 43% to 88%; similarly, between 11% to 59% of
mutation carriers will develop ovarian cancer by the age of 70 [1–
3]. These considerable differences in disease manifestation suggest
the existence of other genetic or environmental factors that modify
the risk of cancer development. The Consortium of Investigators
of Modifiers of BRCA1 and BRCA2 (CIMBA), was established in
2006 [4] and with more than 40,000 mutation carriers currently
provides the largest sample size for reliable evaluation of even
modest associations between single-nucleotide polymorphisms
(SNPs) and cancer risk. CIMBA studies have so far demonstrated
that more than 25 SNPs are associated with the risk of developing
breast or ovarian cancer for BRCA1 or BRCA2 carriers. These
were identified through genome-wide association studies (GWAS)
of breast or ovarian cancer in the general population or through
BRCA1- and BRCA2-specific GWAS [5–8]. Cells harboring
mutations in BRCA1 or BRCA2 show impaired homologous
recombination (HR) [9–11] and are thus critically dependent on
other members of the DNA repair machinery such as poly ADP
ribose polymerase (PARP1) involved in the Base Excision Repair
(BER) pathway. The BER pathway is crucial for the replacement
of aberrant bases generated by different causes [12]. A deficiency
in BER can give rise to a further accumulation of double-strand
DNA breaks which, in the presence of a defective BRCA1 or
BRCA2 background, could persist and lead to cell cycle arrest or
cell death; this makes BRCA-deficient cells extremely sensitive to
PARP inhibitors, as previously demonstrated [13]. We hypothesize
that SNPs in PARP1 and other members of BER may be
associated with cancer risk in BRCA1 and BRCA2 mutation
carriers. SNPs in XRCC1, one of the main components of BER,
have been recently evaluated within the CIMBA consortium [14],
however a comprehensive study has not yet been performed of
either XRCC1 or the other genes participating in BER.
In the present study, we used a tagging SNP approach to
evaluate whether the common genetic variation in the genes
involved in the BER pathway could be associated with cancer risk
in a large series of BRCA1/2 mutation carriers using a two-stage
approach. The first stage involved an analysis of 144 tag SNPs in
1,787 Spanish and Italian BRCA1/2 mutation carriers. In stage II,
the 36 SNPs showing the strongest evidence of association in stage
I, were evaluated in a further 23,463 CIMBA mutation carriers
included in the Collaborative Oncological Gene-environment
Study (COGS) and genotyped using the iCOGS custom genotyp-
ing array.
Results
Breast cancer association
In stage I, 144 selected Tag SNPs covering the 18 selected BER
genes were genotyped in 968 BRCA1 and 819 BRCA2 mutation
carriers from five CIMBA centres (Spanish National Cancer
ResearchCentre (CNIO), Hospital Clı´nico San Carlos (HCSC),
Catalan Institute of Oncology (ICO), Demokritos and Milan
Breast Cancer Study Group (MBCSG). Of those, 50 were
excluded because of low call-rates, minor allele frequency
(MAF),0.05, evidence of deviation from Hardy Weinberg
Equilibrium (p-value,1023) or monomorphism. Associations with
Base Excision Repair Genes Are BRCA1/2 Modifiers
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breast cancer risk were assessed for 94 SNPs, as summarized in
Table S1. The 36 SNPs that showed evidence of association at
p#0.05 were selected for analysis in stage II. Of the 36 SNPs
successfully genotyped in the whole CIMBA series comprising
15,252 BRCA1 and 8211 BRCA2 mutation carriers, consistent
evidence of association with breast cancer risk (p-trend,0.05) was
observed for six SNPs (Table 1). The strongest evidence of
association was observed for rs1466785 in the NEIL2 gene (HR:
1.09, 95% CI (1.03–1.16), p = 2.761023) for association with
breast cancer risk in BRCA2 mutation carriers. We had observed a
consistent association in stage I in BRCA2 mutation carriers (HR:
1.25, p = 0.06). The SNP was primarily associated with ER-
negative breast cancer (HR: 1.20, 95%CI (1.06–1.37),
p = 461023), although the difference in HRs for ER-positive
and ER-negative disease was not statistically significant. The
evidence of association in Stage II was somewhat stronger when
considering the genotype-specific models, with the dominant being
the best fitting (HR: 1.20 95% CI: 1.09–1.37, p = 161024). The
associations remained significant and the estimated effect sizes
remained consistent with the overall analysis when the data were
reanalyzed excluding samples used in stage I of the study (data not
shown). Imputation using the 1000 genomes data showed that
there were several SNPs in strong linkage disequilibrium (LD)
with rs1466785 showing more significant associations (p,1023)
(Figure 1).
Ovarian cancer association
Due to lack of power we did not perform analysis of associations
with ovarian cancer in stage I. However, we performed this
analysis for the 36 SNPs tested in stage II. Although they had been
selected based on their evidence of association with breast cancer
risk, under the initial hypothesis they are also plausible modifiers of
ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. We
found four SNPs associated with ovarian cancer risk with a p-
trend,0.01 in BRCA1 or BRCA2 mutation carriers (Table 1). The
strongest association was found for rs2304277 in OGG1 in BRCA1
mutation carriers (HR: 1.12, 95%CI: 1.03–1.21, p = 4.861023).
The association was somewhat stronger under the dominant
model (HR: 1.19, 95%CI: 1.08–1.3, p = 661024). Although three
other SNPs were found to be associated with ovarian cancer risk in
BRCA2 mutation carriers (p-trend,1023), these results were based
on a relatively small number of ovarian cancer cases. Imputed data
did not show any SNPs with substantially more significant
associations with ovarian cancer risk except for rs3093926 in
PARP2, associated with ovarian cancer risk in BRCA2 mutation
carriers for which there was a SNP, rs61995542, with a stronger
association (HR: 0.67, p = 4.661024) (Figure S1).
Discussion
Based on the interaction of synthetic lethality that has been
described between PARP1 and both BRCA1 and BRCA2, we
hypothesize that this and other genes involved in the BER
pathway could potentially be associated with cancer risk in
BRCA1/2 mutation carriers. Several studies have recently
investigated the association of some of the BER genes with breast
cancer, however, no definitive conclusions can be drawn, given
that some publications suggest that SNPs in these genes can be
associated with breast cancer risk with marginal p-values while
others rule out a major role of these genes in the disease [15–21].
There is only one study from the CIMBA consortium which has
evaluated the role of three of the most studied SNPs in the XRCC1
gene, c.-77C.T (rs3213245) p.Arg280His (rs25489) and
p.Gln399Arg (rs25487), ruling out associations of these variants
with cancer risk in BRCA1 and BRCA2 mutation carriers [14].
However, a comprehensive analysis of neither XRCC1 nor the
other genes involved in the pathway in the context of BRCA
mutation carriers has been performed. In the present study we
have assessed the common genetic variation of 18 genes
participating in BER by using a two stage strategy.
Eleven SNPs showed evidence of association with breast and/or
ovarian cancer at p,0.05 in stage II of the experiment (Table 1).
Of those, six showed a p-trend value,0.01 and were therefore
considered the best candidates for further evaluation. Only one of
those six, rs1466785 in the NEIL2 gene (endonuclease VIII-like 2)
showed an association with breast cancer risk while the other five,
rs2304277 in OGG1 (8-guanine DNA glycosylase), rs167715 and
rs4135087 in TDG (thymine-DNA glycosylase), rs3093926 in
PARP2 (Poly(ADP-ribose) polymerase 2) and rs34259 in UNG
(uracil-DNA glycosylase) were associated with ovarian cancer risk.
The minor allele of NEIL2-rs1466785 was associated with
increased breast cancer risk in BRCA2 mutation carriers;
moreover, when considering the genotype-specific risks observed
that the best fitting model was the dominant one. NEIL2 is one of
the oxidized base-specific DNA glycosylases that participate in the
initial steps of BER and specifically removes oxidized bases from
transcribing genes [22]. By imputing using the 1000 genome data
we found six correlated SNPs in strong LD with rs1466785
(r2.0.8), located closer or inside the gene and showing slightly
stronger and more significant associations with the disease and
therefore being better candidate causal variants. From those, we
considered rs804276 and rs804271 as the best candidates given
that they showed the most significant associations (p = 661024 and
p = 861024 respectively) and there were available epidemiological
or functional data supporting their putative role in cancer. SNP
rs804276 has been associated with disease recurrence in patients
with bladder cancer treated with Bacillus Calmette-Gue´rin (BCG)
(HR: 2.71, 95%CI (1.75–4.20), p = 961026) [23]. SNP rs804271 is
located in a positive regulatory region in the promoter of the gene,
between two potential cis- binding sites for reactive oxygen species
responsive transcription factors in which sequence variation has
Author Summary
Women harboring a germ-line mutation in the BRCA1 or
BRCA2 genes have a high lifetime risk to develop breast
and/or ovarian cancer. However, not all carriers develop
cancer and high variability exists regarding age of onset of
the disease and type of tumor. One of the causes of this
variability lies in other genetic factors that modulate the
phenotype, the so-called modifier genes. Identification of
these genes might have important implications for risk
assessment and decision making regarding prevention of
the disease. Given that BRCA1 and BRCA2 participate in the
repair of DNA double strand breaks, here we have
investigated whether variations, Single Nucleotide Poly-
morphisms (SNPs), in genes participating in other DNA
repair pathway may be associated with cancer risk in BRCA
carriers. We have selected the Base Excision Repair
pathway because BRCA defective cells are extremely
sensitive to the inhibition of one of its components,
PARP1. Thanks to a large international collaborative effort,
we have been able to identify at least two SNPs that are
associated with increased cancer risk in BRCA1 and BRCA2
mutation carriers respectively. These findings could have
implications not only for risk assessment, but also for
treatment of BRCA1/2 mutation carriers with PARP inhib-
itors.
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been proven to alter the transcriptional response to oxidative stress
[24]. Moreover, this SNP has been proposed to partly explain the
inter-individual variability observed in NEIL2 expression levels in
the general population and has been proposed as a potential risk
modifier of disease susceptibility [25].
Several studies have been published showing associations
between SNPs in NEIL2 and lung or oropharyngeal cancer risk
[26,27] but to our knowledge, no association with breast cancer
risk has been reported. We hypothesize that the potential
association observed in the present study could be explained by
the interaction between NEIL2 and BRCA2, each of them causing
a deficiency in the BER and HR DNA repair pathways,
respectively. This would explain why the breast cancer risk
modification due to rs1466785 would only be detected in the
context of BRCA2 mutation carriers and not in the general
population.
The strongest evidence of association found in BRCA1 carriers
was between rs2304277 in the OGG1 gene and ovarian cancer risk.
The association was more significant when considering the
dominant model. OGG1 removes 8-oxodeoxyguanosine which is
generated by oxidative stress and is highly mutagenic, and it has
been suggested that SNPs in the gene could be associated with
cancer risk [28–31]. This is an interesting result, given that to date
only one SNP, rs4691139 in the 4q35.3 region, also identified
through the iCOGS effort, has been found to modify ovarian
cancer risk specifically in BRCA1 carriers [32]. SNP rs2304277 is
located in the 39UTR (untranslated region) of the gene and is
probably not the causal variant, however, in this case imputations
through the 1000 Genome did not show better results for a more
plausible causal SNP.
We have identified four SNPs associated with ovarian cancer
risk in BRCA2 mutation carriers, rs167715 and rs4135087 in the
TDG gene, rs34259 in the UNG gene and rs3093926 in PARP2.
However, these last results should be interpreted with caution
given that the number of BRCA2 carriers affected with ovarian
cancer is four-fold lower than for BRCA1 carriers and the statistical
power was therefore more limited, increasing the possibility of
false-positives. In the case of PARP2, imputed data showed a lower
p-value of association (461024) for another SNP, rs61995542, that
had a slightly higher MAF than rs3093926 (0.074 vs. 0.067)
(Figure S1). However, it must still be interpreted with caution due
to small number of ovarian cancer cases in the BRCA2 group.
It is worth noting that, four of the five genes for which strongest
evidence of association was observed, are all DNA glycosylases
participating in the initiation of BER by removing damaged or
mismatched bases. Apart from the already mentioned NEIL2 and
OGG1, TDG initiates repair of G/T and G/U mismatches
commonly associated with CpG islands, while UNG removes
uracil in DNA resulting from deamination of cytosine or
replicative incorporation of dUMP. We have not found strong
associations with SNPs in genes involved in any other parts of the
pathway, such as strand incision, trimming of ends, gap filling or
ligation. It has been suggested that at least in the case of uracil
repair, base removal is the major rate-limiting step of BER [33].
This is consistent with our findings, suggesting that SNPs causing
impairment in the function of these specific DNA glycosylases
Figure 1. p-values of association (2log10 scale) with breast cancer risk in BRCA2 carriers for genotyped and imputed SNPs in the
NEIL2 gene. SNP rs1466785 is indicated with a purple arrow and the best causal imputed SNPs, rs804276 and rs804271 are indicated with a red
arrow. Colors represent the pariwise r2. Plot generated with LocusZoom [42] (http://csg.sph.umich.edu/locuszoom/).
doi:10.1371/journal.pgen.1004256.g001
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could give rise to accumulation of single strand breaks and
subsequently DNA double strand breaks that, in the HR defective
context of BRCA1/2 mutation carriers would increase breast and
ovarian cancer risk.
The fact that the SNPs tested are located in genes participating
in the same DNA repair pathway as PARP1, make them especially
interesting, not only as risk modifiers but also because they could
have an impact on patients’ response to treatment with PARP
inhibitors. BRCA1/2 mutation carriers harboring a potential
modifier SNP in DNA glycosylases could be even more sensitive
to PARPi due to a constitutional slight impairment of the BER
activity. This is a hypothesis that should be confirmed in further
studies. The design of this study in two stages, the hypothesis-based
approach adopted to select genes, and that it is based on the
largest possible series of BRCA1 and BRCA2 carriers available
nowadays, mean that the results obtained are quite solid However,
the study still has some limitations such as the possible existence of
residual confounding due to environmental risk factors for which
we did not have information.
In summary, we have identified at least two SNPs, rs1466785
and rs2304277, in the DNA glycolylases NEIL2 and OGG1,
potentially associated with increased breast and ovarian cancer
risks in BRCA2 and BRCA1 mutation carriers, respectively. Our
results suggest that glycosylases involved in the first steps of the
BER pathway may be cancer risk modifiers in BRCA1/2 mutation
carriers and should be more comprehensively studied. If
confirmed, these findings could have implications not only for
risk assessment, but also for treatment of BRCA1/2 mutation
carriers with PARP inhibitors.
Materials and Methods
Subjects
Eligible subjects were female carriers of deleterious mutations in
BRCA1 or BRCA2 aged 18 years or older [6]. A total of 55
collaborating CIMBA studies contributed genotypes for the study.
Numbers of samples included from each are provided in Table S2.
A total of 1,787 mutation carriers (968 with mutations in BRCA1
and 819 with mutations in BRCA2) from the CNIO, HCSC, ICO,
Demokritos and MBCSG were genotyped in the first stage of the
study. Stage II included 23,463 CIMBA samples (15,252 with
mutations in BRCA1 and 8,211 with mutations in BRCA2). All
carriers participated in clinical and/or research studies at the host
institution under IRB-approved protocols.
Methods stage I
Selection and genotyping of SNPs. Eighteen genes (UNG,
SMUG1, MBD4, TDG, OGG1, MUTYH, NTHL1, MPG, NEIL1,
NEIL2, APEX1, APEX2, LIG3, XRCC1, PNKP, POLB, PARP1 and
PARP2) involved in the BER pathway were selected, based on the
information available at http://www.cgal.icnet.uk/
DNA_Repair_Genes.html as at the 31st December, 2009. Tag
SNPs for the selected genes were defined using Haploview v.4.0
(http://www.broad.mit.edu/mpg/haploview) with an r2 threshold
of 0.8 and a minimum minor allele frequency of 0.05. In addition,
SNPs with potentially functional effects already described in the
literature were selected. A final number of 144 SNPs was included
in an oligonucleotide pool assay for genotyping using the Illumina
Veracode technology (Illumina Inc., San Diego, CA). Three
hundred nanograms of DNA from each sample were genotyped
using the GoldenGate Genotyping Assay with Veracode technol-
ogy according to the published Illumina protocol. Genotype
clustering and calling were carried out using the GenomeStudio
software. SNPs with a call rate ,0.95 were excluded from further
analysis. Duplicate samples and CEPH trios (Coriell Cell
Repository, Camden, NJ) were genotyped across the plates. SNPs
showing Mendelian allele-transmission errors or showing discor-
dant genotypes across duplicates were excluded.
Statistical analysis. To test for departure from Hardy-
Weinberg equilibrium (HWE), a single individual was randomly
selected from each family and Pearson’s X2 Test (1df) was applied
to genotypes from this set of individuals. The association of the
SNPs with breast cancer risk was assessed by estimating hazard
ratios (HR) and their corresponding 95% confidence intervals (CI)
using weighted multivariable Cox proportional hazards regression
with robust estimates of variance [34]. For each mutation carrier,
we modeled the time to diagnosis of breast cancer from birth,
censoring at the first of the following events: bilateral prophylactic
mastectomy, breast cancer diagnosis, ovarian cancer diagnosis,
death or date last know to be alive. Subjects were considered
affected if their age at censoring corresponded to their age at
diagnosis of breast cancer and unaffected otherwise. Weights were
assigned separately for carriers of mutations in BRCA1 and
BRCA2, by age and affection status, so that the weighted observed
incidences in the sample agreed with established estimates for
mutation carriers [1]; [34].
We considered log-additive and co-dominant genetic models
and tested for departure from HR = 1 by applying a Wald test
based on the log-HR estimate and its standard error. Additional
independent variables included in all analyses were year of study,
centre and country. All statistical analyses were carried out using
Stata: Release 10 (StataCorp. 2007. Stata Statistical Software:
Release 10.0. College Station, TX: Stata Corporation LP). Robust
estimates of variance were calculated using the cluster subcom-
mand, applied to an identifier variable unique to each family.
Methods stage II
iCOGS SNP array. Stage II of the experiment was
performed as part of the iCOGS genotyping experiment. The
iCOGS custom array was designed in collaboration between the
Breast Cancer Association Consortium (BCAC), the Ovarian
Cancer Association Consortium (OCAC), the Prostate Cancer
Association Group to Investigate Cancer Associated in the
Genome (PRACTICAL) and CIMBA. The final design comprised
211,155 successfully manufactured SNPs of which approximately
17.5% had been proposed by CIMBA. A total of 43 SNPs were
nominated for inclusion on iCOGS based on statistical evidence of
association in stage I of the present study (p#0.05). Of these, 36
were successfully manufactured and genotyped in CIMBA
mutation carriers.
iCOGS genotyping and quality control. Genotyping was
performed at Mayo Clinic and the McGill University and Ge´nome
Que´bec Innovation Centre (Montreal, Canada). Genotypes were
called using Illumina’s GenCall algorithm. Sample and quality
control process have been described in detail elsewhere [32,35].
After the quality control process a total of 23,463 carriers were
genotyped for the 36 selected SNPs.
Statistical analysis. Both breast and ovarian cancer associ-
ations were evaluated in stage II. Censoring for breast cancer
followed the same approach as in stage I. Censoring for ovarian
cancer risk occurred at risk-reducing salpingo-oophorectomy or
last follow-up.
The genotype-disease associations were evaluated within a
survival analysis framework, by modelling the retrospective
likelihood of the observed genotypes conditional on the disease
phenotypes [9,34,36,37]. The associations between genotype and
breast or ovarian cancer risk were assessed using the 1 d.f. score
test statistic based on this retrospective likelihood. To allow for the
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non-independence among related individuals, we accounted for
the correlation between the genotypes by estimating the kinship
coefficient for each pair of individuals using the available genomic
data [34,38,39]. These analyses were performed in R using the
GenABELlibraries and custom-written functions in FORTRAN
and Python.
To estimate the magnitude of the associations (HRs), the effect
of each SNP was modeled either as a per-allele HR (multiplicative
model) or as genotype-specific HRs, and was estimated on the log-
scale by maximizing the retrospective likelihood. The retrospective
likelihood was fitted using the pedigree-analysis software MEN-
DEL. The variances of the parameter estimates were obtained by
robust variance estimation based on reported family membership.
All analyses were stratified by country of residence and based on
calendar-year and cohort-specific breast cancer incidence rates for
mutation carriers. Countries with small number of mutation
carriers were combined with neighbouring countries to ensure
sufficiently large numbers within each stratum. USA and Canada
were further stratified by reported Ashkenazi Jewish (AJ) ancestry.
Imputation. Genotypes were imputed separately for BRCA1
and BRCA2 mutation carriers using the v3 April 2012 release
(Genomes Project et al., 2012) as reference panel. To improve
computation efficiency we used a two-step procedure which
involved pre-phasing in the first step and imputation of the phased
data in the second. Pre-phasing was carried out using the
SHAPEIT software [40]. The IMPUTE version 2 software was
used for the subsequent imputation [41]. SNPs were excluded
from the association analysis if their imputation accuracy was
r2,0.3 or MAF,0.005 in any of the data sets. For the final
analysis we only took in account those SNPs with an imputation
accuracy r2.0.7, MAF.0.01 and being located in the region
comprised within 15 kilo bases (kb) downstream and upstream the
gene where the genotyped SNP showing an association was
located (Table 1). Associations between imputed genotypes and
breast cancer risk were evaluated using a version of the score test
as described above but with the posterior genotype probabilities
replacing the genotypes.
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Figure S1 p-values of association (2log10 scale) with breast and
ovarian cancer risk in BRCA1 and BRCA2 carriers for genotyped
and imputed SNPs considering 15 kb upstream and downstream
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